Aptose Biosciences Inc.

Posters & Presentations

All Poster Presentation
December 6, 2025 Poster

TUSCANY Study Demonstrates Safety and Efficacy of Tuspetinib plus Standard of Care Venetoclax and Azacitidine in Patients with Newly Diagnosed AML Ineligible for Induction Chemotherapy

TUSCANY Study Demonstrates Safety and Efficacy of Tuspetinib plus Standard of Care Venetoclax and Azacitidine in Patients with Newly Diagnosed AML Ineligible for Induction Chemotherapy: View Poster
October 16, 2025 Poster

ESH 2025 Poster - TUSCANY Study of Safety and Efficacy of Tuspetinib plus Standard of Care Venetoclax and Azacitidine in Study Participants with Newly Diagnosed AML Ineligible for Induction Chemotherapy

ESH 2025 Poster - TUSCANY Study of Safety and Efficacy of Tuspetinib plus Standard of Care Venetoclax and Azacitidine in Study Participants with Newly Diagnosed AML Ineligible for Induction Chemotherapy: View Poster
August 21, 2025 Presentation

TUS Triplet TUSCANY Trial Update - August 2025

TUS Triplet TUSCANY Trial Update - August 2025: View Presentation
June 12, 2025 Presentation

EHA 2025 - TUSCANY Study of Safety and Efficacy of Tuspetinib plus Standard of Care Venetoclax and Azacitidine in Study Participants with Newly Diagnosed AML Ineligible for Induction Chemotherapy

EHA 2025 - TUSCANY Study of Safety and Efficacy of Tuspetinib plus Standard of Care Venetoclax and Azacitidine in Study Participants with Newly Diagnosed AML Ineligible for Induction Chemotherapy: View Presentation
May 5, 2025 Presentation

Aptose Corporate Presentation - Bloom Burton Conference

Aptose Corporate Presentation - Bloom Burton Conference: View Presentation
March 11, 2025 Presentation

Aptose Corporate Presentation March 2025

Aptose Corporate Presentation March 2025: View Presentation
January 13, 2025 Presentation

Aptose Corporate Presentation January 2025

Aptose Corporate Presentation January 2025: View Presentation
December 9, 2024 Poster

Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML

Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML: View Poster
November 7, 2024 Presentation

Aptose Corporate Presentation November 2024

Aptose Corporate Presentation November 2024: View Presentation